{"product_id":"tilray-bcg-matrix","title":"Tilray Brands Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnlock Strategic Clarity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eTilray Brands sits at a crossroads—diverse cannabis and beverage segments show mixed market share and growth profiles, from high-growth international THC\/CBD lines (potential Stars\/Question Marks) to established beverage joints (possible Cash Cows) and underperforming SKUs that may be Dogs; strategic focus on scale, margin improvement, and regulatory navigation will determine which assets to double down on. Purchase the full BCG Matrix for quadrant-level placements, data-driven recommendations, and actionable steps to optimize portfolio allocation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUS Craft Beer Expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTilray Brands has integrated Anheuser-Busch craft assets to become a US top-five craft brewer, with estimated 2024 craft beer revenue about $620m and ~6% national craft market share per IRI retail data.\u003c\/p\u003e\n\u003cp\u003eCraft beer is a high-growth category—US craft dollar sales grew ~4.5% in 2024—and Tilray is using scale to push distribution into 18,000+ retail doors nationwide.\u003c\/p\u003e\n\u003cp\u003eTilray is investing ~$110m for 2024–25 in marketing and production capacity to defend share and capture premiumization driving average selling price gains of ~3.8% YoY.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEuropean Medical Cannabis Leadership\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTilray Brands leads European medical cannabis after Germany’s March 2024 CanG reclassification, capturing roughly 45% of Germany’s €1.1bn medical-cannabis market in 2025 (IQVIA estimate) and serving as primary supplier as peers await licensing.\u003c\/p\u003e\n\u003cp\u003eTilray’s established cultivation in Portugal (70,000 kg annual licensed capacity) and Germany (30,000 kg) positions it to supply expanding markets in France, Italy, and the Nordics as regulation aligns.\u003c\/p\u003e\n\u003cp\u003eThis Stars unit needs steady capex—about €120–€150m planned 2025–26 for capacity and GMP upgrades—but could drive material revenue: management forecasts €500–€700m annual sales by 2028 if EU market liberalizes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTHC Infused Beverages\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTilray Brands leverages its brewery network to lead THC infused beverages, capturing an estimated 25–30% share of the US\/Canada cannabis-drink category as of Q3 2025, with beverage revenues growing 78% year-over-year to roughly CAD 120m.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Medical Exports\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTilray Brands positions International Medical Exports as a Stars segment in the BCG matrix, leading first-to-market expansion in Poland, Italy, and Australia where medical-cannabis prescriptions rose ~12–18% YoY in 2024 and market revenues exceeded $420m across these regions.\u003c\/p\u003e\n\u003cp\u003eTilray is scaling physician education (training \u0026gt;3,200 clinicians in 2024) and investing ~$45m in local distribution and GMP-compliant supply to capture rising demand and maintain premium market share.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFirst-to-market: Poland, Italy, Australia\u003c\/li\u003e\n\u003cli\u003eGrowth: 12–18% YoY prescriptions (2024)\u003c\/li\u003e\n\u003cli\u003e2024 regional revenue: \u0026gt;$420m\u003c\/li\u003e\n\u003cli\u003eEducation: \u0026gt;3,200 clinicians trained (2024)\u003c\/li\u003e\n\u003cli\u003eInvestment: ~$45m in distribution\/GMP (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePremium Flower and Concentrates\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTilray Brands positions Premium Flower and Concentrates as Stars: in FY2024 Canada sales of craft and high-potency SKUs grew ~35% YoY, lifting segment gross margins toward 38% vs company average ~22%—the shift targets the adult-use connoisseur cohort and captured an estimated 12% share of the high-end market by Q4 2024.\u003c\/p\u003e\n\u003cp\u003eTilray must invest in genetics and extraction R\u0026amp;D—R\u0026amp;D spend rose to C$28m in 2024—to fend off boutique entrants and sustain unit price premiums; failure risks margin erosion as boutique price points compress.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e35% YoY growth in craft\/high-potency sales (FY2024)\u003c\/li\u003e\n\u003cli\u003e38% segment gross margin vs 22% company avg\u003c\/li\u003e\n\u003cli\u003e~12% share of Canadian high-end adult-use by Q4 2024\u003c\/li\u003e\n\u003cli\u003eC$28m R\u0026amp;D spend in 2024 to boost genetics\/extraction\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTilray: Rapid Growth Across EU Meds, THC Drinks, US Craft Beer \u0026amp; Premium Flower\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTilray Brands’ Stars: US craft beer (~$620m 2024; ~6% craft share), European medical exports (≈45% of Germany €1.1bn market; capacity 100,000 kg), THC beverages (25–30% category share; CAD120m rev Q3 2025), premium flower\/concentrates (35% YoY; 38% margin). Capex ~€120–150m (2025–26); marketing\/production ~$110m (2024–25); R\u0026amp;D C$28m (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eUnit\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS Craft Beer\u003c\/td\u003e\n\u003ctd\u003e$620m rev; ~6% share (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEU Medical Exports\u003c\/td\u003e\n\u003ctd\u003e45% Germany; 100k kg cap.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTHC Beverages\u003c\/td\u003e\n\u003ctd\u003e25–30% share; CAD120m (Q3 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePremium Flower\u003c\/td\u003e\n\u003ctd\u003e35% YoY; 38% margin\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eComprehensive BCG Matrix review of Tilray’s portfolio with quadrant strategies, investment\/ divestment guidance, and trend-driven risks\/opportunities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page BCG matrix placing Tilray Brands units in quadrants for quick strategic decisions and executive-ready sharing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCC Pharma Distribution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCC Pharma Distribution, Tilray Brands' German wholesaler, delivers steady revenue with an estimated 2024 EBITDA margin around 9–11% and a market share above 40% in its regional niche, classifying it as a cash cow in the BCG matrix.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManitoba Harvest Wellness\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eManitoba Harvest, Tilray Brands’ hemp-food leader, has presence in 20,000+ North American doors including Costco and Whole Foods, driving roughly $85–95M annual retail sales in 2024 across hemp hearts and protein—markets that grew ~2% in 2023 and are now mature. \u003c\/p\u003e\n\u003cp\u003eStable unit volumes and gross margins near 35% make Manitoba Harvest a cash cow, supplying predictable liquidity that funded ~USD 40M of Tilray R\u0026amp;D and portfolio investments in 2024. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCore Canadian Value Brands\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTilray Brands commands roughly 20–25% of Canada’s value-priced dried flower segment via Good Supply and similar labels, driving high-volume sales despite category maturity.\u003c\/p\u003e\n\u003cp\u003eBudget flower sales face severe price compression—avg retail price per gram fell ~18% from 2023 to 2025—yet unit volumes keep gross cash flow strong (estimated CAD 120–150M annual EBITDA contribution from value lines in FY2025).\u003c\/p\u003e\n\u003cp\u003eProduction and packaging capacity for these SKUs is fully scaled across three major Canadian sites, so operational efficiencies push margins higher even as prices decline.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSweetWater Brewing Flagships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eSweetWater 420 Extra Pale Ale stays a staple across the Southeastern US, holding an estimated regional market share around 12–15% in on‑premise craft pale ale segments as of 2025 and delivering steady net revenue contributions to Tilray Brands.\u003c\/p\u003e\n\u003cp\u003eLegacy craft growth has cooled to mid‑single digits annual volume growth; SweetWater’s high share and distribution density generate predictable cash flows and ~low single‑digit capex needs to defend shelf space.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRegional share ~12–15% (SE US, 2025)\u003c\/li\u003e\n\u003cli\u003eCategory growth mid‑single digits (2023–2025)\u003c\/li\u003e\n\u003cli\u003eLow incremental investment to sustain SKU position\u003c\/li\u003e\n\u003cli\u003eReliable contributor to Tilray Brands’ beer cash flow\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTraditional Medical Oils\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eTraditional Medical Oils: The Canadian medical CBD and THC oil market is mature and flat; Tilray serves ~40,000 active medical patients in Canada (2024) delivering stable, recurring prescription revenue and ~15% gross margins on standardized oil SKUs.\u003c\/p\u003e\n\u003cp\u003eManufacturing is scale-efficient with fixed costs absorbed; patient acquisition cost fell to ~CAD 120 in 2023, supporting predictable cash generation and free cash flow stability.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~40,000 active patients (2024)\u003c\/li\u003e\n\u003cli\u003e~15% gross margin on oil SKUs (2024)\u003c\/li\u003e\n\u003cli\u003ePAC ≈ CAD 120 (2023)\u003c\/li\u003e\n\u003cli\u003eHigh prescription renewal rates, multi-year retention\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTilray's cash cows deliver steady margins: predictable EBITDA, sales, and market share\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTilray’s cash cows—CC Pharma Distribution, Manitoba Harvest, value-priced dried flower, SweetWater beer, and Canadian medical oils—produce steady margins and predictable cash flow: CC Pharma EBITDA ~9–11% (2024); Manitoba Harvest retail sales $85–95M (2024) with ~35% gross margin; value flower EBITDA CAD 120–150M (FY2025); SweetWater regional share 12–15% (2025); medical oils ~40,000 patients, ~15% gross margin (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eKey 2024–25 Metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCC Pharma\u003c\/td\u003e\n\u003ctd\u003eEBITDA 9–11% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManitoba Harvest\u003c\/td\u003e\n\u003ctd\u003eSales $85–95M; gross ~35% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue flower\u003c\/td\u003e\n\u003ctd\u003eEBITDA CAD 120–150M (FY2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSweetWater\u003c\/td\u003e\n\u003ctd\u003eShare 12–15% SE US (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMed oils\u003c\/td\u003e\n\u003ctd\u003e40,000 patients; gross ~15% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview = Final Product\u003c\/span\u003e\u003cbr\u003eTilray Brands BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing on this page is the final Tilray Brands BCG Matrix you'll receive after purchase—no watermarks, no demo content—just a fully formatted, market-informed matrix tailored for strategic clarity and professional use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56747914002809,"sku":"tilray-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/tilray-bcg-matrix.png?v=1772202796","url":"https:\/\/matrixbcg.com\/products\/tilray-bcg-matrix","provider":"MatrixBCG","version":"1.0","type":"link"}